Clinical Trial: A Study to Learn More About the Long-Term Safety of Tofersen (Qalsody) in Chinese Participants With SOD-1 Amyotrophic Lateral Sclerosis (ALS)

U.S., Nov. 4 -- ClinicalTrials.gov registry received information related to the study (NCT07223723) titled 'A Study to Learn More About the Long-Term Safety of Tofersen (Qalsody) in Chinese Participants With SOD-1 Amyotrophic Lateral Sclerosis (ALS)' on Oct. 31.

Brief Summary: In this study, researchers will learn more about the safety of tofersen, also known as Qalsody(R). This is a drug available for doctors to prescribe for people with a certain type of amyotrophic lateral sclerosis, also known as ALS. This type is in people who have a mutation in the superoxide dismutase 1 gene, also known as SOD-1.

This is known as a "postmarketing" study. In this kind of the study, the goal is to learn more about how a drug works after it has been a...